Introduction
Sunlenca (lenacapavir) is a long-acting antiretroviral medication used in combination with other antiretroviral medications to treat HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1. It works differently from traditional HIV medication classes by targeting the HIV-1 capsid and interfering with several stages of the viral lifecycle.
Sunlenca may also be used as part of the oral loading regimen when initiating Bixlenvo in certain adults whose HIV-1 is already virologically suppressed. For eligible patients who need help managing prescription costs, Prescription Hope may provide access assistance for $70.00 per month, per medication, subject to program eligibility and availability.
What Is the Sunlenca Patient Assistance Program?
When looking for Sunlenca and HIV prescription assistance, patients may come across the Sunlenca patient assistance program. However, most may not understand what a patient assistance program is.
Patient assistance programs are offered to qualified patients by the manufacturers of brand-name medications. These programs provide approved patients access to their brand-name medication at affordable rates.
Unfortunately, many of these programs require a complex application process that many Americans find difficult to navigate.
Prescription Hope can help.
How Expert Advocates Help Make Sunlenca More Affordable
Prescription Hope provides personalized medication assistance services and advocacy to qualified patients nationwide. Our team of patient advocates helps patients access affordable medications.
We offer personalized advocacy and support services to our trained team alongside patients going through the patient assistance program application process. We complete forms, collect documents, gather healthcare provider signatures, coordinate with manufacturers, and more.
Ongoing Prescription Assistance
However, we don’t just help during the application process. Our team continues to manage the administrative tasks associated with patient assistance program approval. We manage refill scheduling, document updates, issue resolution, yearly renewal, and program monitoring.
Sunlenca Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Simplified Access to Specialty Therapies
Our HIV medication assistance services help patients focus on the more important things in life and live without worrying about expensive medication costs.
Prescription Hope’s service rate is a simple $70.00 per month, per medication. That means no hidden fees, no add-ons, and no medication costs.
And if we can’t help you save, then you pay nothing.
Sunlenca Patient Assistance Eligibility
Curious to learn more about Sunlenca enrollment eligibility? Be sure to fill out Prescription Hope’s enrollment form today and find out more from one of our dedicated patient advocates.
Patient assistance programs maintain rigorous standards in several key categories:
Income: Each program maintains its own criteria regarding approved income range
Insurance: Programs vary regarding insurance coverage status.
Prescription: All programs require a valid prescription for the approved brand-name medication.
Residency: All programs require patients to be legal U.S. residents.
Simple Enrollment With Expert Support
Ready for your Sunlenca enrollment? To get started with your prescription assistance application, simply follow these 6 steps:
- Submit Information: Fill out our secure online enrollment form in a matter of minutes.
- Advocate Contact: A patient advocate will reach out within 1-2 business days of submission.
- Document Collection: After a quick prequalification, we collect all necessary documents.
- Provider Coordination: We also connect with your healthcare provider to gather needed signatures.
- Program Submission: Once it’s all in order, we submit your application and coordinate with the manufacturer throughout the processing stage.
- Medication Delivery: After approval, qualified patients usually receive their medication within 2 weeks. All medication ships directly from the manufacturer to the patient’s house or doctor’s office.
Prescription Hope is not a manufacturer or pharmacy. We do not at any time handle medications.
Understanding Sunlenca
How Sunlenca Works
Sunlenca contains lenacapavir, an HIV-1 capsid inhibitor that works by binding directly to the interface between HIV-1 capsid protein subunits. This interferes with several essential stages of the HIV lifecycle.
Lenacapavir interferes with capsid-mediated nuclear uptake of viral DNA, virus assembly and release, and formation of the capsid core. This provides an antiretroviral mechanism distinct from the major traditional HIV drug classes.
What Conditions Does Sunlenca Treat?
Sunlenca is indicated in combination with other antiretroviral medications for heavily treatment-experienced adults with multidrug-resistant HIV-1 whose current antiretroviral regimen is failing because of resistance, intolerance, or safety considerations.
Sunlenca is also used for oral loading when initiating Bixlenvo in adults who are virologically suppressed on a stable antiretroviral regimen and have no known or suspected resistance to the individual components of Bixlenvo.
Benefits of Treatment
Sunlenca provides a long-acting treatment option for appropriately selected adults with multidrug-resistant HIV-1. In the CAPELLA trial, Sunlenca produced substantial reductions in HIV-1 RNA during the functional monotherapy period, and maintenance treatment consists of subcutaneous injections every 6 months when used with an appropriate antiretroviral regimen.
Important Safety Information and Side Effects
Immune Reconstitution Syndrome
As with other antiretroviral therapies, an inflammatory response to residual or previously hidden infections can occur after treatment begins. This is known as immune reconstitution syndrome.
Long-Acting Properties and Resistance
Lenacapavir can remain in systemic circulation for 12 months or longer after the final injection. Missing scheduled injections or discontinuing treatment without an effective alternative antiretroviral regimen can result in loss of virologic response and development of resistance.
If Sunlenca is discontinued, an alternative fully suppressive antiretroviral regimen should, where possible, be initiated no later than 28 weeks after the final injection.
Persistent Drug Interactions
Lenacapavir is a moderate CYP3A inhibitor and can increase exposure to certain medications metabolized by CYP3A. Some interactions can remain clinically relevant for months after the final Sunlenca injection.
Patients should review prescription medications, over-the-counter medicines, and herbal products with their healthcare provider before and during treatment.
Injection-Site Reactions
Injection-site reactions are common with Sunlenca and may include swelling, pain, redness, nodules, induration, itching, extravasation, or a mass. Nodules and induration may persist considerably longer than other injection-site reactions.
Improper administration, including intradermal injection, has been associated with serious reactions such as necrosis and ulceration. Sunlenca must be administered subcutaneously in the abdomen by a healthcare professional.
Drug Interactions and Contraindicated Medications
Sunlenca is contraindicated with strong CYP3A inducers because they can substantially reduce lenacapavir concentrations and potentially result in loss of therapeutic effect and development of resistance.
Important medications and substances include carbamazepine, phenytoin, rifampin, and St. John’s wort, which are contraindicated. Moderate CYP3A inducers such as oxcarbazepine, phenobarbital, rifabutin, and rifapentine are not recommended.
Other medications may also require management because Sunlenca can increase their exposure. These include certain opioids, PDE-5 inhibitors, oral midazolam, triazolam, direct oral anticoagulants, and some statins.
Pregnancy and Breastfeeding
Available human pregnancy data have not identified a drug-associated increase in miscarriage or adverse maternal or fetal outcomes compared with an active control, but the number of exposed pregnancies remains limited. A pregnancy exposure registry is available.
Lenacapavir is present in human milk, and very low levels have been detected in breastfed infants. No adverse effects in breastfed infants have been observed in the available data, although effects on milk production are unknown. For people with HIV, breastfeeding also carries potential risks related to HIV-1 transmission, infant resistance, and adverse reactions.
Common Side Effects
The most common adverse reactions reported in heavily treatment-experienced adults receiving Sunlenca were injection-site reactions and nausea. Injection-site reactions occurred in 65% of patients and nausea occurred in 4% of patients in the CAPELLA trial.
Access to Multiple Medications
Those looking for HIV medication assistance often need multiple medications to treat certain conditions and side effects.
Prescription Hope’s services cover access to hundreds of brand-name medications. Our $70.00 per month, per medication is the same, no matter how many medications you qualify for.
Why Choose Prescription Hope for Sunlenca Assistance?
Patient-Focused Medication Support
After two decades, Americans nationwide continue to trust Prescription Hope’s team of patient advocates with their prescription assistance support and advocacy.
Simplified Access to Specialty Therapies
All of our services are included in our simple $70.00 per month, per medication.
Ongoing Prescription Assistance
Prescription Hope not only helps patients complete their application process, but we also manage the administrative tasks required after acceptance. We offer refill scheduling, document updates, issue resolution, yearly renewals, and program monitoring. All for the same low service fee.
If you’re looking for personalized prescription assistance services and need HIV medication support, then be sure to enroll with Prescription Hope today.